| Peggy Jo Whiteplume, OD | |
|
America's Best, 1805 Se Delaware Ave Suite 1000, Ankeny, IA 50021 | |
| (515) 333-5845 | |
| (515) 333-5846 |
| Full Name | Peggy Jo Whiteplume |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | America's Best, Ankeny, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649334905 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 18002415A (Indiana) | Secondary |
| 152W00000X | Optometrist | 01905 (Iowa) | Primary |
| Provider Name | Us Health Dept Of Health & Human Services |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1972694602 PECOS PAC ID: 9638081623 Enrollment ID: O20031106000399 |
News Archive
Increased awareness of breast tissue density masking cancer and thus decreasing the diagnostic sensitivity of mammography has brought about relevant state-level policies.
On Sept. 12, Harris Health System celebrated the completion of Smith Clinic, the system's first outpatient specialty facility. The new facility enhances and expands specialty care for patients formerly seen at hospital-based clinics located at Ben Taub Hospital.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "Identification of a Novel Class of HCV Inhibitors". Published in the January 20th edition of Science and Translational Medicine, the research validates a domain, termed 4BAH2, within the non-structural protein (NS4B) of the HCV genome, as essential for HCV replication and describes the development of a high-throughput screen leading to the identification of small molecule inhibitors of 4BAH2.
Human papillomavirus (HPV) was found to be the main risk factor associated with increased incidence of an unusual type of cervical cancer called cervical adenocarcinoma, according to a study in the March 1 issue of the Journal of the National Cancer Institute.
Results of two studies funded by Project A.L.S. and appearing in the advance online publication of Nature Neuroscience demonstrate that embryonic stem cells may provide a new tool for studying disease mechanisms and for identifying drugs to slow ALS, also known as Lou Gehrig's disease.
› Verified 6 days ago
| Provider Name | Wind River Family & Community Health Care |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1285006379 PECOS PAC ID: 1850683780 Enrollment ID: O20160713000531 |
News Archive
Increased awareness of breast tissue density masking cancer and thus decreasing the diagnostic sensitivity of mammography has brought about relevant state-level policies.
On Sept. 12, Harris Health System celebrated the completion of Smith Clinic, the system's first outpatient specialty facility. The new facility enhances and expands specialty care for patients formerly seen at hospital-based clinics located at Ben Taub Hospital.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "Identification of a Novel Class of HCV Inhibitors". Published in the January 20th edition of Science and Translational Medicine, the research validates a domain, termed 4BAH2, within the non-structural protein (NS4B) of the HCV genome, as essential for HCV replication and describes the development of a high-throughput screen leading to the identification of small molecule inhibitors of 4BAH2.
Human papillomavirus (HPV) was found to be the main risk factor associated with increased incidence of an unusual type of cervical cancer called cervical adenocarcinoma, according to a study in the March 1 issue of the Journal of the National Cancer Institute.
Results of two studies funded by Project A.L.S. and appearing in the advance online publication of Nature Neuroscience demonstrate that embryonic stem cells may provide a new tool for studying disease mechanisms and for identifying drugs to slow ALS, also known as Lou Gehrig's disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peggy Jo Whiteplume, OD Peggy Whiteplume, 839 S. 6th St., Lander, WY 82520 Ph: (307) 349-5196 | Peggy Jo Whiteplume, OD America's Best, 1805 Se Delaware Ave Suite 1000, Ankeny, IA 50021 Ph: (515) 333-5845 |
News Archive
Increased awareness of breast tissue density masking cancer and thus decreasing the diagnostic sensitivity of mammography has brought about relevant state-level policies.
On Sept. 12, Harris Health System celebrated the completion of Smith Clinic, the system's first outpatient specialty facility. The new facility enhances and expands specialty care for patients formerly seen at hospital-based clinics located at Ben Taub Hospital.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "Identification of a Novel Class of HCV Inhibitors". Published in the January 20th edition of Science and Translational Medicine, the research validates a domain, termed 4BAH2, within the non-structural protein (NS4B) of the HCV genome, as essential for HCV replication and describes the development of a high-throughput screen leading to the identification of small molecule inhibitors of 4BAH2.
Human papillomavirus (HPV) was found to be the main risk factor associated with increased incidence of an unusual type of cervical cancer called cervical adenocarcinoma, according to a study in the March 1 issue of the Journal of the National Cancer Institute.
Results of two studies funded by Project A.L.S. and appearing in the advance online publication of Nature Neuroscience demonstrate that embryonic stem cells may provide a new tool for studying disease mechanisms and for identifying drugs to slow ALS, also known as Lou Gehrig's disease.
› Verified 6 days ago
Child And Family Vision Center, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2525 N Ankeny Blvd, Ste. 109, Ankeny, IA 50023 Phone: 515-964-7541 Fax: 515-964-7568 | |
Dr. Morgan Elizabeth Wichman, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1805 Se Delaware Ave Ste 900, Ankeny, IA 50021 Phone: 515-333-5845 | |
Dr. Lisa R. Brooks, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 119 N. Ankeny Blvd, Eye Mart Optical, Ankeny, IA 50023 Phone: 515-965-8858 Fax: 515-965-7966 | |
Korth Eye Care Llc Optometrist Medicare: Medicare Enrolled Practice Location: 2135 Se Delaware Ave, Ankeny, IA 50021 Phone: 515-964-0444 | |
Domino Eye Care, Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2510 Sw White Birch Dr Ste 5, Ankeny, IA 50023 Phone: 515-964-5427 Fax: 515-964-3277 | |
Walter Forrest Joyner, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1002 Se National Dr, Ankeny, IA 50021 Phone: 515-963-1112 | |
Semrow Family Vision, Pc Optometrist Medicare: Medicare Enrolled Practice Location: 1304 Nw 25th St, Ankeny, IA 50023 Phone: 515-965-0909 |